Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusis

Abstract

Purpose: To evaluate whether topical ketorolac tromethamine can reduce the adverse effect of laser in situ keratomileusis (LASIK). Design: A prospective randomized controlled clinical study. Participants: Nineteen patients who underwent bilateral simultaneous LASIK performed at Siriraj Hospital. Intervention: Patients received two drops of ketorolac tromethamine in one eye immediately after surgery. Main Outcome Measures: Symptoms of tearing, photophobia, foreign body sensation and pain were evaluated at 30 minutes, 6 hours and 24 hours. Results: There was no statistically significant difference in symptoms at 30 minutes. At 6 and 24 hours, ketorolac-treated eyes had significantly fewer symptoms compared to non-treated eyes. Conclusions: Ketorolac tromethamine reduces some unfavorable symptoms within the first 24 hours after LASIK.